A novel heterogeneous catalytic hydrogenation-hydrogenolysis strategy has been developed for the α-methylation of ketones via enaminones using DMF dimethyl acetal as carbon source. This strategy provides a very convenient route to α-methylated ketones using a variety of ketones without any base or oxidant.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.joc.5b00084DOI Listing

Publication Analysis

Top Keywords

dmf dimethyl
8
dimethyl acetal
8
acetal carbon
8
carbon source
8
α-methylation ketones
8
hydrogenation-hydrogenolysis strategy
8
source α-methylation
4
ketones
4
ketones hydrogenation-hydrogenolysis
4
strategy enaminones
4

Similar Publications

Potential therapeutic effect of dimethyl fumarate on Treg/Th17 cell imbalance in biliary atresia.

Clin Immunol

January 2025

Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai Key Laboratory of Birth Defect, and Key Laboratory of Neonatal Disease, Ministry of Health, Shanghai 201102, China. Electronic address:

The imbalance between Tregs and proinflammatory Th17 cells in children with biliary atresia (BA) causes immune damage to cholangiocytes. Dimethyl fumarate (DMF), an immunomodulatory drug, regulates the Treg/Th17 balance in diseases like multiple sclerosis (MS). This study explores DMF's effect on Treg/Th17 balance in BA and its potential mechanism.

View Article and Find Full Text PDF

Dimethyl Fumarate attenuates synovial inflammation, reduces nociception, and inhibits the development of post-traumatic osteoarthritis.

Biomed Pharmacother

January 2025

Joseph Maxwell Cleland Atlanta VA Medical Center, Decatur, GA 30033, USA; Department of Orthopaedics, Emory Musculoskeletal Institute, Emory University, Atlanta, GA 30329, USA. Electronic address:

There is currently no cure or disease-modifying treatment for post-traumatic osteoarthritis (PTOA). This study aims to assess the efficacy of dimethyl fumarate (DMF), a US-FDA approved drug for multiple sclerosis, as a treatment for PTOA. PTOA was induced in male Lewis rats by medial meniscal transection (MMT) surgery, and DMF was intra-articularly administered once, one week following surgery.

View Article and Find Full Text PDF

Background/objectives: The impact of vaccines against SARS-CoV-2 on the immunity of patients with multiple sclerosis (PwMS) is still not fully known. Further clarification could help address medical concerns related to the use of immunosuppressive and immunomodulatory medications, known as disease-modifying therapies (DMTs), in PwMS, as well as ensure adequate protection against severe outcomes of COVID-19. Therefore, the aim of our study was to evaluate the humoral and cellular immune response in PwMS treated with DMTs.

View Article and Find Full Text PDF

Background: Multiple sclerosis (MS) is an autoimmune disorder affecting the central nervous system, with varying clinical manifestations such as optic neuritis, sensory disturbances, and brainstem syndromes. Disease progression is monitored through methods like MRI scans, disability scales, and optical coherence tomography (OCT), which can detect retinal thinning, even in the absence of optic neuritis. MS progression involves neurodegeneration, particularly trans-synaptic degeneration, which extends beyond the initial injury site.

View Article and Find Full Text PDF

Background: Dimethyl fumarate (DMF) and diroximel fumarate (DRF) are two treatments used for multiple sclerosis (MS) that have been shown to be effective in controlling MS patients. DRF was introduced in 2019 with the aim of decreasing the gastrointestinal side effects caused by DMF. Few real-life studies verify the data provided in the clinical trials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!